K Pharma (TSE:4896) EV-to-FCF: (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4896 K Pharma Inc TSE:4896
11 GF Score
Price 円719.00
! 1 Warning Sign
View Full Analysis

What is K Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, K Pharma's Enterprise Value is 円7,298.46 Mil. K Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil. Therefore, K Pharma's EV-to-FCF for today is .

The historical rank and industry rank for K Pharma's EV-to-FCF or its related term are showing as below:

TSE:4896' s EV-to-FCF Range Over the Past 10 Years
Min: -7.98   Med: 0   Max: 0
Current: -7.98

TSE:4896's EV-to-FCF is ranked worse than
100% of 335 companies
in the Biotechnology industry
Industry Median: 15.34 vs TSE:4896: -7.98

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-14), K Pharma's stock price is 円719.00. K Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-42.720. Therefore, K Pharma's PE Ratio (TTM) for today is At Loss.


K Pharma  (TSE:4896) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

K Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=719.00/-42.720
=At Loss

K Pharma's share price for today is 円719.00.
K Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-42.720.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


K Pharma EV-to-FCF Related Terms


K Pharma EV-to-FCF Historical Data

* Premium members only.

The historical data trend for K Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

K Pharma EV-to-FCF Chart

K Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 11.45 -4.95 -6.86

K Pharma Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -6.86 0.00

TSE:4896 vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, K Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


K Pharma EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, K Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where K Pharma's EV-to-FCF falls into.


TSE:4896
11GF Score
K Pharma Inc TSE:4896
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

K Pharma EV-to-FCF Calculation

K Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7298.456/0
=

K Pharma's current Enterprise Value is 円7,298.46 Mil.
K Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


K Pharma Business Description

Address 7-7-7 Roppongi, Tri-Seven Roppongi 8th Floor, Minato-ku, Tokyo, JPN, 106-0032
K Pharma Inc is a company involved in Research, development, manufacturing, sales, and marketing of pharmaceutical products and regenerative medicine products. It is involved in the study of iPs cells in regenerative medicine to treat neurological conditions such as cerebral infarction and SCI.
11GF Score

Get the complete analysis for TSE:4896

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円719.00
Price